Description: <b>Gambogic acid</b> is a naturally occurring xanthonoid extracted from the resin of trees belonging to the Garcinia genus—most notably, Garcinia hanburyi. This tree is native to regions in Southeast Asia, particularly found in areas of China, India, and neighboring countries.<br>
Gambogic acid (GA; C38H44O8, MW: 628.76), a polyprenylated xanthone and a widely used coloring agent, is the main active ingredient of gamboges secreted from the Garcinia hanburyi tree ([3, 4], which mainly grows in Southeast Asia. <br>
GA has been approved by the Chinese FDA for the treatment of solid cancers in Phase II clinical trials.<br>
<br>
Pathways:<br>
-evidence suggesting that it can inhibit thioredoxin reductase (TrxR).<br>
-can indeed lead to an increase in reactive oxygen species (ROS) levels<br>
-Gambogic acid can trigger mitochondrial dysfunction, leading to cytochrome c release<br>
-influences death receptors<br>
-Inhibition of NF-κB Signaling<br>
-Inhibition of VEGF Pathway<br>
-Cell Cycle Arrest:<br>
-p53 Activation<br>
<p><b>Gambogic acid</b> — a naturally occurring, highly prenylated caged xanthone isolated principally from gamboge resin produced by <i>Garcinia hanburyi</i>. It is an experimental small-molecule anticancer agent commonly abbreviated GA or GBA, with the molecular formula C<sub>38</sub>H<sub>44</sub>O<sub>8</sub>. GA is an electrophilic, multi-target compound whose α,β-unsaturated carbonyl groups can covalently modify reactive cysteine residues in redox-regulatory and proteostasis proteins. It has undergone limited Phase I and Phase IIa clinical investigation in China as an intravenous formulation but is not an established or broadly approved anticancer drug.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Covalent inhibition of thioredoxin and thioredoxin reductase, with additional inhibition of PRDX1 and related thiol-dependent antioxidant systems, causing collapse of tumor-cell redox buffering.</li>
<li>ROS accumulation followed by mitochondrial membrane depolarization, cytochrome-c release, Bax/Bcl-2 imbalance, caspase activation, apoptosis, and in some models GSDME-dependent pyroptosis.</li>
<li>Covalent inhibition of 6-phosphogluconate dehydrogenase, suppressing the oxidative pentose phosphate pathway, NADPH generation, and antioxidant regeneration.</li>
<li>Disruption of thiol proteostasis, proteasome function, HSP90-dependent client-protein stability, and endoplasmic-reticulum homeostasis, producing ER stress, unfolded-protein responses, autophagy, paraptosis, or apoptosis.</li>
<li>Suppression of PI3K–AKT–mTOR, NF-κB, STAT3, survivin, and other pro-survival signaling pathways.</li>
<li>Cell-cycle arrest through context-dependent activation of p53 and p21 and suppression of cyclin D1 and related proliferative regulators.</li>
<li>Inhibition of angiogenesis, invasion, and metastasis through reduced HIF-1α, VEGF, MMP-2, MMP-9, and epithelial–mesenchymal transition signaling.</li>
<li>Chemosensitization and reversal of multidrug resistance through inhibition of P-glycoprotein, survivin, NF-κB, and stress-adaptation pathways; radiosensitization has also been reported preclinically.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> GA is highly lipophilic, poorly water-soluble, chemically reactive, and rapidly distributed and metabolized. Human studies have used intravenous GA formulations rather than conventional oral dosing. A major circulating human metabolite is 10-hydroxygambogic acid. Short systemic persistence, formulation-dependent exposure, local irritation, and limited aqueous solubility have driven extensive investigation of liposomes, albumin carriers, polymeric nanoparticles, solid-lipid nanoparticles, and other targeted delivery systems. Preclinical toxicology identifies the liver and kidney as principal dose-limiting target organs, with potential drug-interaction concerns related to CYP3A4 and transporter modulation.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> Many mechanistic studies use approximately micromolar GA concentrations and short, direct cellular exposure. These conditions may produce greater free-drug exposure than is safely sustained in plasma or tissues because GA is poorly soluble, extensively protein-bound, rapidly metabolized, and systemically toxic at higher exposure. Covalent target engagement may permit biological activity despite transient exposure, but concentration-dependent cell-culture findings should not be assumed to translate directly to achievable unencapsulated systemic dosing.</p>
<p><b>Clinical evidence status:</b> Predominantly preclinical, with limited small-human evidence. An open-label, randomized, multicentre Phase IIa study evaluated different intravenous dosing schedules in patients with advanced solid malignancies and reported mainly grade 1–2 adverse effects, but the study was small, lacked a placebo or standard-treatment control, and did not establish definitive efficacy. There is no robust confirmatory randomized trial evidence, no established survival benefit, and no routine clinical role. GA should therefore be classified as an investigational natural-product-derived anticancer agent rather than an approved chemotherapy.</p>
<h3>Gambogic Acid Mechanistic Ranking</h3>
<table border="1" cellspacing="0" cellpadding="4">
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Thioredoxin and thioredoxin reductase inhibition</td>
<td>↓ Trx1, Trx2 and TrxR activity</td>
<td>↓ antioxidant capacity possible</td>
<td>P</td>
<td>Redox-buffering collapse</td>
<td>Core electrophilic mechanism involving covalent modification of catalytic or regulatory cysteine residues.</td>
</tr>
<tr>
<td>2</td>
<td>Peroxiredoxin and thiol proteostasis</td>
<td>↓ PRDX1 function; ↓ thiol proteostasis</td>
<td>Potential oxidative and proteotoxic injury</td>
<td>P–R</td>
<td>Loss of peroxide detoxification and protein homeostasis</td>
<td>PRDX1 has been identified as a direct covalent target; target relevance may vary by tumor type.</td>
</tr>
<tr>
<td>3</td>
<td>Reactive oxygen species accumulation</td>
<td>↑ ROS</td>
<td>↑ ROS at sufficient exposure</td>
<td>P–R</td>
<td>Oxidative-stress overload</td>
<td>Central downstream consequence of antioxidant-system inhibition; not inherently cancer-selective.</td>
</tr>
<tr>
<td>4</td>
<td>Pentose phosphate pathway and 6PGD</td>
<td>↓ 6PGD; ↓ PPP; ↓ NADPH</td>
<td>↓ NADPH possible</td>
<td>R</td>
<td>Metabolic and antioxidant restriction</td>
<td>GA covalently inhibits 6PGD, limiting NADPH production and reinforcing oxidative stress.</td>
</tr>
<tr>
<td>5</td>
<td>Mitochondrial membrane integrity</td>
<td>↓ membrane potential; ↑ cytochrome c release</td>
<td>Mitochondrial toxicity possible</td>
<td>R</td>
<td>Intrinsic apoptosis initiation</td>
<td>Frequently linked to ROS, p53, Bax activation, and Bcl-2 suppression.</td>
</tr>
<tr>
<td>6</td>
<td>Apoptosis and pyroptosis execution</td>
<td>↑ caspase-3, caspase-8 and caspase-9; ↑ GSDME cleavage</td>
<td>Cell death possible at toxic exposure</td>
<td>R–G</td>
<td>Programmed cell death</td>
<td>Predominantly apoptosis; GSDME-dependent pyroptosis occurs in selected GSDME-expressing models.</td>
</tr>
<tr>
<td>7</td>
<td>Endoplasmic reticulum stress and unfolded-protein response</td>
<td>↑ PERK, ATF6, GRP78 and CHOP signaling</td>
<td>ER stress possible</td>
<td>R–G</td>
<td>Proteotoxic stress and apoptosis</td>
<td>Usually secondary to ROS accumulation, covalent protein modification, and proteostasis disruption.</td>
</tr>
<tr>
<td>8</td>
<td>Proteasome and HSP90 chaperone function</td>
<td>↓ proteasome activity; ↓ HSP90 client stability</td>
<td>Proteostasis toxicity possible</td>
<td>R–G</td>
<td>Oncoprotein destabilization</td>
<td>May reduce AKT, HER2, survivin, and other short-lived or chaperone-dependent proteins.</td>
</tr>
<tr>
<td>9</td>
<td>PI3K AKT mTOR survival signaling</td>
<td>↓ PI3K; ↓ p-AKT; ↓ mTOR</td>
<td>Context-dependent suppression</td>
<td>R–G</td>
<td>Reduced growth and stress adaptation</td>
<td>May be partly downstream of oxidative stress and degradation of signaling proteins.</td>
</tr>
<tr>
<td>10</td>
<td>NF-κB and STAT3 signaling</td>
<td>↓ NF-κB; ↓ STAT3; ↓ survivin</td>
<td>↓ inflammatory signaling possible</td>
<td>R–G</td>
<td>Reduced survival and inflammatory transcription</td>
<td>Contributes to apoptosis, reduced invasion, and sensitization to cytotoxic therapy.</td>
</tr>
<tr>
<td>11</td>
<td>Cell-cycle checkpoints</td>
<td>↑ p53 and p21; ↓ cyclin D1; ↑ arrest</td>
<td>Growth arrest possible</td>
<td>G</td>
<td>Proliferation blockade</td>
<td>Checkpoint and arrest phase vary among tumor models.</td>
</tr>
<tr>
<td>12</td>
<td>Autophagy and paraptosis</td>
<td>↑ autophagy; ↑ vacuolization; ↑ paraptosis</td>
<td>Context-dependent stress response</td>
<td>G</td>
<td>Adaptive or non-apoptotic cell death</td>
<td>Autophagy may be protective or cytotoxic; chloroquine can enhance GA activity in some models.</td>
</tr>
<tr>
<td>13</td>
<td>HIF-1α VEGF angiogenesis axis</td>
<td>↓ HIF-1α; ↓ VEGF; ↓ angiogenesis</td>
<td>Potential impairment of physiological angiogenesis</td>
<td>G</td>
<td>Reduced tumor vascular support</td>
<td>Preclinical effect; systemic antiangiogenic selectivity is not established.</td>
</tr>
<tr>
<td>14</td>
<td>Invasion and metastasis</td>
<td>↓ MMP-2; ↓ MMP-9; ↓ migration; ↓ EMT</td>
<td>Limited direct evidence</td>
<td>G</td>
<td>Reduced invasive phenotype</td>
<td>Likely integrates NF-κB, PI3K–AKT, HIF-1α, and cytoskeletal signaling effects.</td>
</tr>
<tr>
<td>15</td>
<td>Chemosensitization and drug resistance</td>
<td>↓ P-gp; ↓ survivin; ↑ chemotherapy sensitivity</td>
<td>↑ combination toxicity possible</td>
<td>G</td>
<td>Resistance reversal</td>
<td>Synergy reported with doxorubicin, cisplatin, docetaxel, chloroquine, and other agents in preclinical models.</td>
</tr>
<tr>
<td>16</td>
<td>Radiosensitization</td>
<td>↑ radiation-induced ROS and cell death</td>
<td>Potential ↑ normal-tissue radiation injury</td>
<td>R–G</td>
<td>Enhanced radiation response</td>
<td>Preclinical and context-dependent; therapeutic selectivity remains uncertain.</td>
</tr>
<tr>
<td>17</td>
<td>Clinical Translation Constraint</td>
<td>Exposure limited by solubility, metabolism, formulation and heterogeneity</td>
<td>Kidney, liver and local irritation risks</td>
<td>G</td>
<td>Restricted therapeutic window</td>
<td>Poor aqueous solubility, short systemic persistence, covalent off-target activity, CYP and transporter interactions, and weak controlled clinical evidence limit translation.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
older table (left here for references)
<table border="1" cellspacing="0" cellpadding="4">
<tr>
<th>Rank</th>
<th>Pathway / Target Axis</th>
<th>Direction</th>
<th>Primary Effect</th>
<th>Notes / Cancer Relevance</th>
<th>Ref</th>
</tr>
<tr>
<td>1</td>
<td>Thioredoxin / Thioredoxin reductase (Trx / TrxR)</td>
<td>↓ Trx / TrxR activity</td>
<td>Redox buffering collapse</td>
<td>Primary molecular target; covalent cysteine interaction drives loss of antioxidant capacity</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC5652772/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>2</td>
<td>ROS accumulation</td>
<td>↑ ROS</td>
<td>Oxidative stress overload</td>
<td>Immediate consequence of Trx/TrxR inhibition; upstream of mitochondrial damage</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7484097/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>3</td>
<td>Mitochondrial integrity (ΔΨm)</td>
<td>↓ ΔΨm</td>
<td>Mitochondrial dysfunction</td>
<td>GA reduces mitochondrial membrane potential prior to execution-phase death</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3626980/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>4</td>
<td>Intrinsic apoptosis / pyroptosis (caspase-3, GSDME)</td>
<td>↑ programmed cell death</td>
<td>Execution-phase killing</td>
<td>Mitochondrial apoptosis and caspase-3/GSDME-dependent pyroptosis reported</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3626980/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>5</td>
<td>NF-κB signaling</td>
<td>↓ NF-κB activation</td>
<td>Reduced pro-survival transcription</td>
<td>Redox-sensitive suppression of NF-κB nuclear activity and target genes</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2077305/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>6</td>
<td>PI3K–AKT survival signaling</td>
<td>↓ AKT phosphorylation</td>
<td>Survival pathway collapse</td>
<td>Downstream of oxidative stress and chaperone disruption</td>
<td><a href="https://www.jcancer.org/v11p5568.htm" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>7</td>
<td>HSP90 chaperone function</td>
<td>↓ client stabilization</td>
<td>Oncoprotein destabilization</td>
<td>GA disrupts HSP90–client interactions affecting AKT, HER2, etc.</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/18077578/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>8</td>
<td>ER stress / UPR</td>
<td>↑ ER stress signaling</td>
<td>Proteotoxic stress</td>
<td>Secondary ER stress response following redox and mitochondrial disruption</td>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/31138775/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>9</td>
<td>Cell cycle regulation</td>
<td>↑ cell-cycle arrest</td>
<td>Proliferation blockade</td>
<td>Checkpoint activation downstream of stress signaling</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7764553/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>10</td>
<td>Autophagy (stress-induced)</td>
<td>↑ autophagy</td>
<td>Adaptive or pro-death response</td>
<td>Autophagy induction reported; role varies by context</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC7764553/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>11</td>
<td>Angiogenesis signaling (VEGF)</td>
<td>↓ VEGF expression</td>
<td>Anti-angiogenic effect</td>
<td>Suppression of pro-angiogenic transcription observed</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC2077305/" target="_blank">(ref)</a></td>
</tr>
<tr>
<td>12</td>
<td>Tumor growth in vivo</td>
<td>↓ tumor volume</td>
<td>Integrated outcome</td>
<td>Xenograft models show significant tumor growth inhibition</td>
<td><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3626980/" target="_blank">(ref)</a></td>
</tr>
</table>